1. For sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists to be used as first-line agents for type ...
1. This population-based cohort study demonstrated that among older adults with type 2 diabetes, sodium-glucose cotransporter-2 inhibitor (SGLT-2i) use was ...
1. Tirzepatide treatment significantly reduced body weight and fat composition in obese patients while improving cardiometabolic risk factors and physical ...
1. GLP-1 receptor agonists, such as semaglutide, and phentermine-topiramate were shown to cause the greatest percent decrease in body weight. ...
1. From baseline to 52 weeks, tirzepatide resulted in a greater reduction in mean HbA1c levels compared to insulin glargine. ...
1. Patients receiving tirzepatide (5, 10, or 15 mg) reported significantly greater reductions in HbA1c compared to daily insulin degludec ...
1. Tirzepatide was superior to placebo with regard to changes in HbA1c, serum glucose, body weight loss, and proportion of ...
1. Semaglutide 2.4 mg combined with once weekly cagrilintide therapy was not associated with increase in adverse events compared to ...
1. Change in mean bodyweight was -9.6% with semaglutide 2.4 mg vs. -3.4% with placebo. 2. Approximately two-thirds of patients ...
1. No significant difference in severe UTIs was observed between patients starting SGLT-2 inhibitors for type 2 diabetes, compared to ...
